We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+7.88%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4B
AUM Growth
-$191M
(-4.5%)
Cap. Flow
-$236M
Cap. Flow
% of AUM
-5.9%
Top 10 Holdings %
Top 10 Hldgs %
48.84%
Holding
128
New
18
Increased
19
Reduced
24
Closed
26
Avg Time Held Equity + Options
10
quarters
Top 10 Avg Time Held Equity + Options
6.8
quarters
Top 20 Avg Time Held Equity + Options
6.6
quarters
Avg Time Held Equity only
10.6
quarters
Top 10 Avg Time Held Equity only
6.8
quarters
Top 20 Avg Time Held Equity only
6.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Caris Life Sciences
CAI
|
+$81.8M |
| 2 |
UnitedHealth
UNH
|
+$51.6M |
| 3 |
Roivant Sciences
ROIV
|
+$30.1M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$23.2M |
| 5 |
Jade Biosciences
JBIO
|
+$18.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$97.6M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$76.6M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$56.9M |
| 4 |
SpringWorks Therapeutics
SWTX
|
+$41.9M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$34.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.99% |
| 2 | Miscellaneous | 1.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
InspireMD
NSPR
$24.3M
| $4.84M | 0.12% |
2,133,405
| – | – |
2023 Q2
8 quarters
|
|
77
Avalo Therapeutics
AVTX
$651M
| $4.83M | 0.12% |
967,000
| – | – |
2024 Q3
3 quarters
|
|
78
ImageneBio Inc
IMA
$47.7M
| $4.74M | 0.12% |
294,947
| – | – |
2021 Q1
17 quarters
|
|
79
DELISTED
Repare Therapeutics
RPTX
| $4.62M | 0.12% |
3,322,488
| – | – |
2020 Q2
20 quarters
|
|
80
CALL
CG Oncology
CGON
$5.57B
| $3.9M | 0.1% |
+150,000
| New | +$3.61M |
2025 Q2
0 quarters
|
|
81
Immatics
IMTX
$1.04B
| $3.87M | 0.1% |
719,901
-2,367,561
| -77% | -$11.7M |
2023 Q1
9 quarters
|
|
82
BioAge Labs
BIOA
$256M
| $3.81M | 0.1% |
921,959
| – | – |
2024 Q3
3 quarters
|
|
83
Q32 Bio
QTTB
$240M
| $3.36M | 0.08% |
2,252,987
| – | – |
2024 Q1
5 quarters
|
|
84
enGene Therapeutics
ENGN
$109M
| $2.47M | 0.06% |
677,977
-213,639
| -24% | -$802K |
2024 Q4
2 quarters
|
|
85
Passage Bio
PASG
$11.7M
| $2.42M | 0.06% |
302,765
-48,966
| -14% | -$358K |
2020 Q1
21 quarters
|
|
86
Amylyx Pharmaceuticals
AMLX
$3.38B
| $2.01M | 0.05% |
313,200
-34,800
| -10% | -$169K |
2024 Q4
2 quarters
|
|
87
DELISTED
Mural Oncology
MURA
| $1.45M | 0.04% |
+588,800
| New | +$1.39M |
2025 Q2
0 quarters
|
|
88
Insmed
INSM
$21.1B
| $1.35M | 0.03% |
13,459
-15,200
| -53% | -$1.16M |
2024 Q4
2 quarters
|
|
89
Krystal Biotech
KRYS
$9.57B
| $1.26M | 0.03% |
9,200
-14,300
| -61% | -$2.1M |
2023 Q4
6 quarters
|
|
90
DELISTED
Turnstone Biologics
TSBX
| $1.11M | 0.03% |
3,099,265
| – | – |
2023 Q3
7 quarters
|
|
91
Chemomab Therapeutics
CMMB
$9.16M
| $1.09M | 0.03% |
235,248
-200,070
| -46% | -$990K |
2021 Q1
17 quarters
|
|
92
Traws Pharma
TRAW
$6.3M
| $896K | 0.02% |
605,531
| – | – |
2024 Q2
4 quarters
|
|
93
DELISTED
Kezar Life Sciences
KZR
| $883K | 0.02% |
192,700
| – | – |
2022 Q2
12 quarters
|
|
94
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| $866K | 0.02% |
+50,000
| New | +$926K |
2025 Q2
0 quarters
|
|
95
Alto Neuroscience
ANRO
$877M
| $550K | 0.01% |
250,000
| – | – |
2024 Q4
2 quarters
|
|
96
DELISTED
DIH Holdings US
DHAI
| $469K | 0.01% |
76,600
| – | – |
2025 Q1
1 quarter
|
|
97
Lyell Immunopharma
LYEL
$186M
| $457K | 0.01% |
+51,727
| New | +$471K |
2025 Q2
0 quarters
|
|
98
Korro Bio
KRRO
$130M
| $405K | 0.01% |
32,400
| – | – |
2024 Q4
2 quarters
|
|
99
Xeris Biopharma Holdings
XERS
$1.86B
| $376K | 0.01% |
80,420
| – | – |
2024 Q1
5 quarters
|
|
100
PUT
INmune Bio
INMB
$46.3M
| $116K | ﹤0.01% |
+50,000
| New | +$367K |
2025 Q2
0 quarters
|
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q2 2025 Portfolio in Review
As of Q2 2025, OrbiMed held 128 positions worth $4B, down 4.5% from $4.19B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
OrbiMed withdrew a net $236M in Q2 2025, closing 26 positions and reducing 24 holdings. Its most notable exit was Pfizer, an estimated $97.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in Caris Life Sciences worth $81.1M.
- OrbiMed's largest Q2 2025 buy was Caris Life Sciences: 3,034,858 shares worth $81.1M.
- OrbiMed added most to UnitedHealth in Q2 2025, an estimated $51.6M increase.
- OrbiMed's biggest Q2 2025 reduction was Neurocrine Biosciences, cutting an estimated $56.9M.
- OrbiMed fully exited Pfizer in Q2 2025, selling an estimated $97.6M.
- OrbiMed's ten largest holdings make up 49% of its $4B portfolio in Q2 2025.
- OrbiMed opened 18 new positions and closed 26 in Q2 2025.
- OrbiMed's portfolio value fell 4.5% quarter-over-quarter to $4B.
Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.